Q1 2025 Management View Interim CEO Dawn Bir emphasized the company’s primary focus on driving the U.S. commercial success of RYTELO, Geron’s telomerase inhibitor for lower-risk MDS. Q1 2025 net ...

Panelists discuss how the MOMENTUM trial demonstrated momelotinib’s superiority over danazol in symptomatic anemic myelofibrosis patients, showing significant improvements in symptoms (the primary end ...

Jason Weiner has benefited from the opportunity to participate in a myelofibrosis clinical trial at MSK. He is shown here with his wife, Cori, children Dominik, Kasia, and Damian, and dog Babka around ...

About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jain ...

The results offer some of the first glimpses into real-world findings of the Janus kinase inhibitor in patients with ...

Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment ...

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from ...

According to Future Market Insights, myelofibrosis (mf) treatment market is expected to grow at a CAGR of 5.5% between 2023 and 2033, reaching USD 1,280 Million by 2033. The market is expected to ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

Reduction in spleen volume of ≥35% from baseline at week 24 was met in 65.9 and 35.2% of patients randomly assigned to pelabresib-ruxolitinib and placebo-ruxolitinib, respectively. HealthDay ...